C000191143 Fees and Costs — Putnam PanAgora Risk Parity Fund, Class B
Data updated: 2023-11-13
The net expense ratio is 2.08% (2.56% before fee waivers). This share class carries a deferred sales charge of up to 5.00%. Portfolio turnover was 0%.
C000191143 Fees and Expenses
Annual operating expenses and sales charges of C000191143. Prospectus, as of December 31, 2022.
| Annual operating expenses | |
|---|---|
| Management fee | 0.75% |
| 12b-1 fee | 1.00% |
| Other expenses | 0.78% |
| Gross expense ratio | 2.56% |
| Fee waiver | −0.48% |
| Net expense ratio | 2.08% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 5.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
C000191143 Costs Over Time
On $10,000 invested in C000191143, assuming 5% a year before costs, total costs come to $1,273 over 5 years, cutting the return by 2.18% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $514 | $0 | $0 |
| Fund expenses (net expense ratio 2.08%) | $218 | $674 | $1,155 |
| Lost growth on money paid in costs | $0 | $34 | $118 |
| Total costs | $732 | $707 | $1,273 |
| Value after costs | $9,768 | $10,869 | $11,490 |
| Impact on return, per year | 7.32% | 2.18% | 2.18% |
C000191143 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending August 31, 2023.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 0%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.